Venrock Healthcare Capital Partners II is a Private Equity Fund in New York with $149.29 mm assets under management. It has 41 beneficial owners. Data from SEC filing.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry
SEC CIK
AUM ?
$149.29 mm
Address
Venrock Healthcare Capital Partners II
7 BRYANT PARK
23RD FLOOR
NEW YORK
NY 10018
7 BRYANT PARK
23RD FLOOR
NEW YORK
NY 10018
Phone
650 475 3734
Ownership
Fund structure | AUM | Fund type |
---|---|---|
VR Adviser, LLC | $2.02 bn | |
Venrock Healthcare Capital Partners Eg, L.P. | $515.75 mm | Hedge Fund |
Venrock Healthcare Capital Partners II, L.P. | $149.29 mm | Private Equity Fund |
Venrock Healthcare Capital Partners III, L.P. | $554.10 mm | Private Equity Fund |
Venrock Healthcare Capital Partners, L.P. | $1.42 mm | Private Equity Fund |
Venrock Opportunities Fund, L.P. | $678.40 mm | Private Equity Fund |
VHCP Co-investment Holdings II, LLC | $65.10 mm | Private Equity Fund |
Venrock Associates VI, L.P. | ||
Venrock Associates VII, L.P. | ||
Venrock Partners VI, L.P. | ||
Venrock Partners VII, L.P. | ||
VHCP Co-investment Holdings III, LLC | $55.43 mm | Private Equity Fund |
Venrock Associates VIII, L.P. | ||
Venrock Partners VIII, L.P. | ||
VHCP Co-investment Holdings, LLC | $359.87 k | Private Equity Fund |
Venrock Associates V, L.P. | ||
Venrock Partners V, L.P |
Latest filings (excl ownership)
Latest ownership filings
SC 13G/A
DBV Technologies S.A.
14 Feb 24
SC 13G/A
Trevi Therapeutics, Inc.
14 Feb 24
SC 13G/A
Annexon, Inc.
14 Feb 24
SC 13G/A
Savara Inc
14 Feb 24
SC 13G/A
Lyra Therapeutics, Inc.
14 Feb 24
SC 13G/A
GH Research PLC
14 Feb 24
SC 13G/A
Inozyme Pharma, Inc.
14 Feb 24
SC 13G/A
Cogent Biosciences, Inc.
14 Feb 24
SC 13G/A
Aclaris Therapeutics, Inc.
14 Feb 24
SC 13G/A
Axsome Therapeutics, Inc.
14 Feb 23